These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25116835)

  • 21. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
    Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
    J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients.
    Moreau M; Carmona-Iragui M; Altuna M; Dalzon L; Barroeta I; Vilaire M; Durand S; Fortea J; Rebillat AS; Janel N
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
    Jin N; Yin X; Gu J; Zhang X; Shi J; Qian W; Ji Y; Cao M; Gu X; Ding F; Iqbal K; Gong CX; Liu F
    J Biol Chem; 2015 Jun; 290(24):15219-37. PubMed ID: 25918155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased plasma DYRK1A with aging may protect against neurodegenerative diseases.
    Delabar JM; Lagarde J; Fructuoso M; Mohammad A; Bottlaender M; Doran E; Lott I; Rivals I; Schmitt FA; Head E; Sarazin M; Potier MC
    Transl Psychiatry; 2023 Apr; 13(1):111. PubMed ID: 37015911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
    Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
    Yin X; Jin N; Shi J; Zhang Y; Wu Y; Gong CX; Iqbal K; Liu F
    Sci Rep; 2017 Apr; 7(1):619. PubMed ID: 28377597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.
    Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ
    J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer's disease model mice and macaques.
    Zhou FQ; Jiang J; Griffith CM; Patrylo PR; Cai H; Chu Y; Yan XX
    Alzheimers Res Ther; 2018 Apr; 10(1):40. PubMed ID: 29690919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periodic Variation of AAK1 in an Aβ
    Fu X; Ke M; Yu W; Wang X; Xiao Q; Gu M; Lü Y
    J Mol Neurosci; 2018 Jun; 65(2):179-189. PubMed ID: 29774516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.
    Noll C; Planque C; Ripoll C; Guedj F; Diez A; Ducros V; Belin N; Duchon A; Paul JL; Badel A; de Freminville B; Grattau Y; Bléhaut H; Herault Y; Janel N; Delabar JM
    PLoS One; 2009 Oct; 4(10):e7540. PubMed ID: 19844572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.
    Imamura T; Yanagihara YT; Ohyagi Y; Nakamura N; Iinuma KM; Yamasaki R; Asai H; Maeda M; Murakami K; Irie K; Kira JI
    Neurobiol Dis; 2020 Apr; 137():104739. PubMed ID: 31927145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer's disease and mild cognitive impairment.
    Lu R; Wang J; Tao R; Wang J; Zhu T; Guo W; Sun Y; Li H; Gao Y; Zhang W; Fowler CJ; Li Q; Chen S; Wu Z; Masters CL; Zhong C; Jing N; Wang Y; Wang Y
    Mol Psychiatry; 2018 Mar; 23(3):767-776. PubMed ID: 28696436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.